Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients
- PMID: 25532077
- DOI: 10.1016/j.jad.2014.11.058
Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients
Abstract
Background: Gender differences in treatment that are not supported by empirical evidence have been reported in several areas of medicine. Here, the aim was to evaluate potential gender differences in the treatment for bipolar disorder.
Methods: Data was collected from the Swedish National Quality Assurance Register for bipolar disorder (BipoläR). Baseline registrations from the period 2004-2011 of 7354 patients were analyzed. Multiple logistic regression analysis was used to study the impact of gender on interventions.
Results: Women were more often treated with antidepressants, lamotrigine, electroconvulsive therapy, benzodiazepines, and psychotherapy. Men were more often treated with lithium. There were no gender differences in treatment with mood stabilizers as a group, neuroleptics, or valproate. Subgroup analyses revealed that ECT was more common in women only in the bipolar I subgroup. Contrariwise, lamotrigine was more common in women only in the bipolar II subgroup.
Limitations: As BipoläR contains data on outpatient treatment of persons with bipolar disorder in Sweden, it is unclear if these findings translate to inpatient care and to outpatient treatment in other countries.
Conclusions: Men and women with bipolar disorder receive different treatments in routine clinical settings in Sweden. Gender differences in level of functioning, bipolar subtype, or severity of bipolar disorder could not explain the higher prevalence of pharmacological treatment, electroconvulsive therapy, and psychotherapy in women. Our results suggest that clinicians׳ treatment decisions are to some extent unduly influenced by patients׳ gender.
Keywords: Bipolar disorder; Drug therapy; Electroconvulsive therapy; Gender; Psychotherapy.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Treatments for late-life bipolar disorder.Am J Geriatr Pharmacother. 2006 Dec;4(4):347-64. doi: 10.1016/j.amjopharm.2006.12.007. Am J Geriatr Pharmacother. 2006. PMID: 17296540 Review.
-
Changes in mood stabilizer prescription patterns in bipolar disorder.J Affect Disord. 2016 May;195:50-6. doi: 10.1016/j.jad.2016.01.043. Epub 2016 Feb 2. J Affect Disord. 2016. PMID: 26859073
-
International prescribing patterns for mood illness: the International Mood Network (IMN).J Affect Disord. 2014;167:136-9. doi: 10.1016/j.jad.2014.05.049. Epub 2014 Jun 2. J Affect Disord. 2014. PMID: 24955565
-
[Changes in prescription patterns to patients with bipolar syndromes. Increased use of lamotrigine and decreased use of lithium].Lakartidningen. 2014 Dec 16;111(51-52):2284-6. Lakartidningen. 2014. PMID: 25514669 Swedish.
-
Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association.Am J Psychiatry. 1994 Dec;151(12 Suppl):1-36. doi: 10.1176/ajp.151.12.1. Am J Psychiatry. 1994. PMID: 7977902 Review. No abstract available.
Cited by
-
The low risk for early renal damage during lithium treatment has not changed over time.J Psychopharmacol. 2023 Mar;37(3):318-324. doi: 10.1177/02698811221123054. Epub 2022 Sep 19. J Psychopharmacol. 2023. PMID: 36121029 Free PMC article.
-
Has Bipolar Disorder become a predominantly female gender related condition? Analysis of recently published large sample studies.Int J Bipolar Disord. 2021 Jan 4;9(1):3. doi: 10.1186/s40345-020-00207-z. Int J Bipolar Disord. 2021. PMID: 33392912 Free PMC article.
-
Comparison of Genetic Liability for Sleep Traits Among Individuals With Bipolar Disorder I or II and Control Participants.JAMA Psychiatry. 2020 Mar 1;77(3):303-310. doi: 10.1001/jamapsychiatry.2019.4079. JAMA Psychiatry. 2020. PMID: 31751445 Free PMC article.
-
Evidence of lithium underuse in bipolar disorder: analysis of lithium and antipsychotic consumption, prediction of future trends, regional disparities and indicators of rational and inappropriate use in Europe.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 28. doi: 10.1007/s00210-025-04389-0. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40580313
-
Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder.Mol Psychiatry. 2016 Sep;21(9):1290-7. doi: 10.1038/mp.2015.165. Epub 2015 Oct 27. Mol Psychiatry. 2016. PMID: 26503763 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials